Nonadhesive Liquid Embolic Agent for Cerebral Arteriovenous Malformations: Preliminary Histopathological Studies in Swine Rete Mirabile

Nonadhesive Liquid Embolic Agent for Cerebral Arteriovenous Malformations: Preliminary... AbstractOBJECTIVETo assess acute and chronic histopathological changes observed in a swine arteriovenous malformation model after endovascular delivery of Embolyx E (Micro Therapeutics Inc., San Clemente, CA) and its organic solvent dimethyl sulfoxide (DMSO). To develop standard endovascular delivery techniques of Embolyx through microcatheters into swine rete mirabile (RMB).METHODSForty RMBs in 22 swine were used to analyze acute and chronic angiographic and histological changes after superselective delivery of Embolyx E and/or its organic solvent (DMSO). Four RMBs (two for DMSO and two for Embolyx E study) were used as control specimens. Angiographic and histological evaluations were obtained 18 days, 1 month, 3 months, and 6 months after the procedure. Particular attention was paid to the presence of focal or diffuse angionecrosis, arterial revascularization, and perivascular inflammatory response.RESULTSStaged and/or continuous delivery of Embolyx E were performed through the DMSO-compatible microcatheters without untoward catheter “gluing.” All subacute/chronic specimens embolized with Embolyx E showed no evidence of angiographic recanalization. Twelve RMBs were used in acute studies, and all specimens showed no evidence of angionecrosis or aggressive inflammatory reaction. Subacute and chronic (total, n = 14) histological examinations of the RMBs showed mild inflammatory response manifested by monocellular intiltration and scattered foreign body giant cell reaction. In the 9 of 14 subacute and chronic specimens, focal disruption of elastica was observed along with embolic materials. Fourteen RMBs in eight swine were used to determine the safety range for DMSO injection. Two RMBs were used as control specimens. Rapid intra-arterial delivery (0.5 ml/5-15 s, n = 6) of DMSO caused angiographic vasospasm and histological endothelial necrosis-Slow injection (0.5 ml/30-120 s, n = 8 ) of DMSO showed minimum or no angiographic vasospasm, minimal adventitial inflammatory response, and no clinical complications.CONCLUSIONEmbolyx E, an occlusive and nonadhesive embolic agent, is capable of producing permanent occlusion of swine RMB with the development of mild intra- and perivascular inflammatory changes and no clinical complications. The slow endovascular delivery of DMSO produces no untoward angiographic, pathological, or clinical changes. A fast injection of DMSO causes endothelial necrosis and severe inflammatory response in the arterial wall. This embolic material seems to have appropriate biochemical, anatomic, and histopathological characteristics to he used in the treatment of cerebral arteriovenous malformations or vascular cranial base tumors. (Neurosurgery 43:1164-1 175, 1998) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Nonadhesive Liquid Embolic Agent for Cerebral Arteriovenous Malformations: Preliminary Histopathological Studies in Swine Rete Mirabile

Nonadhesive Liquid Embolic Agent for Cerebral Arteriovenous Malformations: Preliminary Histopathological Studies in Swine Rete Mirabile

EXPERIM EN TA L S T U D IE S Nonadhesive Liquid Embolic Agent for Cerebral Arteriovenous Malformations: Preliminary Histopathological Studies in Swine Rete Mirabile Yuichi Murayama, M.D., Fernando Vinuela, M.D., Alexandre Ulhoa, M.D., Yoichi Akiba, M.D., Gary R. Duckwiler, M.D., Y. Pierre Gobin, M.D., Harry V. Vinters, M.D., Richard J. Greff, Ph.D. Divisions ot Interventional Neuroradiology (YM, FV, AU, YA, GRD, YPG) and Neuropathology (HVV) and Leo G. Rigler Radiological Research Center, University of California, Los Angeles, School of Medicine, Los Angeles, and Micro Therapeutics Inc. (R|G), San Clemente, California O B JE C T IV E : To assess acute and chronic histopathological changes observed in a swine arteriovenous malformation model after endovascular delivery of Embolyx E (Micro Therapeutics Inc., San Clemente, CA ) and its organic solvent dimethyl sulfoxide (D M SO ). To develop standard endovascular delivery techniques of Embolyx through microcatheters into swine rete mirabile (RMB). M E T H O D S : Forty RMBs in 22 swine were used to analyze acute and chronic angiographic and histological changes after superselective delivery of Embolyx E and/or its organic solvent (D M SO ). Four RMBs (two for DM SO and two for Embolyx E study) were used as control specimens. Angiographic and histological evaluations were obtained 1 8 days, 1 month, 3 months, and 6 months after the procedure. Particular attention was paid to the presence of focal or diffuse angionecrosis, arterial revascularization, and perivascular inflammatory response. RESULTS: Staged and/or continuous delivery of Embolyx E were performed through the DM SO-compatible micro­ catheters without untoward catheter "gluing." All subacute/chronic specimens embolized with Embolyx E showed no evidence of angiographic recanalization. Twelve RMBs were used in acute studies, and all specimens showed no evidence of angionecrosis or aggressive inflammatory reaction. Subacute and chronic (total, n...
Loading next page...
 
/lp/ou_press/nonadhesive-liquid-embolic-agent-for-cerebral-arteriovenous-zeX54bKtdh
Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199811000-00081
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVETo assess acute and chronic histopathological changes observed in a swine arteriovenous malformation model after endovascular delivery of Embolyx E (Micro Therapeutics Inc., San Clemente, CA) and its organic solvent dimethyl sulfoxide (DMSO). To develop standard endovascular delivery techniques of Embolyx through microcatheters into swine rete mirabile (RMB).METHODSForty RMBs in 22 swine were used to analyze acute and chronic angiographic and histological changes after superselective delivery of Embolyx E and/or its organic solvent (DMSO). Four RMBs (two for DMSO and two for Embolyx E study) were used as control specimens. Angiographic and histological evaluations were obtained 18 days, 1 month, 3 months, and 6 months after the procedure. Particular attention was paid to the presence of focal or diffuse angionecrosis, arterial revascularization, and perivascular inflammatory response.RESULTSStaged and/or continuous delivery of Embolyx E were performed through the DMSO-compatible microcatheters without untoward catheter “gluing.” All subacute/chronic specimens embolized with Embolyx E showed no evidence of angiographic recanalization. Twelve RMBs were used in acute studies, and all specimens showed no evidence of angionecrosis or aggressive inflammatory reaction. Subacute and chronic (total, n = 14) histological examinations of the RMBs showed mild inflammatory response manifested by monocellular intiltration and scattered foreign body giant cell reaction. In the 9 of 14 subacute and chronic specimens, focal disruption of elastica was observed along with embolic materials. Fourteen RMBs in eight swine were used to determine the safety range for DMSO injection. Two RMBs were used as control specimens. Rapid intra-arterial delivery (0.5 ml/5-15 s, n = 6) of DMSO caused angiographic vasospasm and histological endothelial necrosis-Slow injection (0.5 ml/30-120 s, n = 8 ) of DMSO showed minimum or no angiographic vasospasm, minimal adventitial inflammatory response, and no clinical complications.CONCLUSIONEmbolyx E, an occlusive and nonadhesive embolic agent, is capable of producing permanent occlusion of swine RMB with the development of mild intra- and perivascular inflammatory changes and no clinical complications. The slow endovascular delivery of DMSO produces no untoward angiographic, pathological, or clinical changes. A fast injection of DMSO causes endothelial necrosis and severe inflammatory response in the arterial wall. This embolic material seems to have appropriate biochemical, anatomic, and histopathological characteristics to he used in the treatment of cerebral arteriovenous malformations or vascular cranial base tumors. (Neurosurgery 43:1164-1 175, 1998)

Journal

NeurosurgeryOxford University Press

Published: Nov 1, 1998

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off